A detailed history of Bank Of America Corp transactions in Exact Sciences Corp stock. As of the latest transaction made, Bank Of America Corp holds 1,295,047 shares of EXAS stock, worth $60.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,295,047
Previous 1,195,899 8.29%
Holding current value
$60.6 Million
Previous $88.5 Million 1.09%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$56.27 - $73.77 $5.58 Million - $7.31 Million
99,148 Added 8.29%
1,295,047 $89.4 Million
Q4 2023

Feb 14, 2024

SELL
$59.06 - $75.72 $8.52 Million - $10.9 Million
-144,344 Reduced 10.77%
1,195,899 $88.5 Million
Q2 2023

Aug 14, 2023

SELL
$62.68 - $95.05 $38.4 Million - $58.3 Million
-612,887 Reduced 31.38%
1,340,243 $126 Million
Q1 2023

May 12, 2023

BUY
$47.19 - $70.77 $29.5 Million - $44.2 Million
624,706 Added 47.03%
1,953,130 $132 Million
Q4 2022

Feb 10, 2023

BUY
$30.35 - $53.15 $7.81 Million - $13.7 Million
257,326 Added 24.02%
1,328,424 $65.8 Million
Q3 2022

Nov 14, 2022

BUY
$31.97 - $49.37 $3.17 Million - $4.9 Million
99,310 Added 10.22%
1,071,098 $34.8 Million
Q2 2022

Aug 12, 2022

BUY
$35.61 - $76.23 $635,816 - $1.36 Million
17,855 Added 1.87%
971,788 $38.3 Million
Q1 2022

May 16, 2022

SELL
$57.56 - $82.54 $1.33 Million - $1.91 Million
-23,120 Reduced 2.37%
953,933 $66.7 Million
Q4 2021

Feb 08, 2022

SELL
$72.5 - $100.68 $8.56 Million - $11.9 Million
-118,105 Reduced 10.78%
977,053 $76 Million
Q3 2021

Nov 15, 2021

BUY
$90.24 - $124.05 $2 Million - $2.76 Million
22,212 Added 2.07%
1,095,158 $105 Million
Q2 2021

Sep 13, 2021

BUY
$93.66 - $139.27 $100 Million - $149 Million
1,072,946 New
1,072,946 $133 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $8.28B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.